scPharmaceuticals Inc. (SCPH)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Product revenues, net | 16,041 | 11,752 | 10,026 | |
| Selling, general and administrative | 21,226 | 21,407 | 21,320 | |
| Research and development | 4,098 | 4,631 | 3,541 | |
| Cost of product revenues | 5,011 | 3,471 | 3,311 | |
| Total operating expenses | 30,335 | 29,509 | 28,172 | |
| Loss from operations | -14,294 | -17,757 | -18,146 | |
| Interest income | 509 | 716 | 903 | |
| Interest expense | 1,401 | 1,385 | 1,850 | |
| Change in fair value of term loan | 150 | -300 | 2,954 | |
| Change in fair value of revenue purchase and sale liability | 2,560 | 1,752 | 1,830 | |
| Other (expense) income | -128 | 136 | 1,804 | |
| Loss on extinguishment of debt | - | - | -13,032 | |
| Net loss | -18,024 | -19,742 | -35,105 | |
| Comprehensive loss | -18,024 | -19,742 | -35,105 | |
| Net loss per share, basic | -0.34 | -0.37 | -0.75 | |
| Net loss per share, diluted | -0.34 | -0.37 | -0.75 | |
| Weighted-average shares used in computing net loss per share, basic | 53,719,662 | 53,676,376 | 46,558,474 | |
| Weighted-average shares used in computing net loss per share, diluted | 53,719,662 | 53,676,376 | 46,558,474 | |